Britain's National Health Service is taking a good look at how Americans do ACOs. But the move toward accountable care in England has already gotten mired in disputes (and confusion) about what organizational form it should take and whether current proposals are legal.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Depression and Other Mood Disorders Across the Lifespan: Roles of the Obstetrician-Gynecologist.
Obstet Gynecol Clin North Am
March 2025
Department of Obstetrics and Gynecology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA.
Mood disorders such as depressive or bipolar disorders are more common among women. This review provides the fundamentals of diagnosing and treating mood disorders throughout a woman's lifespan. The etiology of mood disorders is not well-understood, but genetic, social, environmental, and neurobiologic factors play roles.
View Article and Find Full Text PDFRelationship between nurse staffing during labor and cesarean birth rates in U.S. hospitals.
Nurs Outlook
January 2025
Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA.
Background: Cesarean birth increases risk of maternal morbidity and mortality.
Purpose: Examine the relationship between labor and delivery staffing and hospital cesarean and vaginal birth after cesarean (VBAC) rates.
Methods: Survey of U.
Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.
Drugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review.
CNS Drugs
January 2025
Faculty of Environmental and Life Sciences, Centre for Innovation in Mental Health, School of Psychology, University of Southampton, Southampton, UK.
Background: Raynaud syndrome (RS) is a peripheral vasculopathy characterised be impaired acral perfusion typically manifesting as skin discolouration with pallor, cyanosis and/or erythema, and increased sensitivity to cold. RS may be primary or secondary to systemic disease, lifestyle and environmental factors or medication. RS has been reported with medication to treat ADHD, but we found no recent comprehensive overview of the literature.
View Article and Find Full Text PDFImproving child and adolescent health and well-being in Europe: the imperative for a new regional strategy.
Pediatr Res
January 2025
WHO Regional Office for Europe, Copenhagen, Denmark.
Despite significant progress during the Millennium Development Goals era, recent trends show stagnation or regression in key health indicators for children and adolescents in Europe. Obesity rates are rising, adolescent mental health is deteriorating, the digital environment poses risks, breastfeeding rates are low, many children face developmental risks, and displaced children encounter significant health challenges. To address these issues, we need a comprehensive strategy for children and adolescents in Europe, leading to increased investment, protection from commercial harm, effective governance, and accountability to improve health outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!